ndabere
Amara ọgwụgwọ dabere na Incretin ogologo oge iji meziwanye ha abụọnjikwa glucose ọbaranaMbelata arọ ahụ. Ọgwụ incretin ọdịnala na-elekwasị anya naGLP-1 nnabata, mgbeTirzepatidena-anọchi anya ọgbọ ọhụrụ nke "twincretin" ndị nnọchiteanya - na-eme ihema GIP (glucose-based insulinotropic polypeptide)naGLP-1ndị na-anabata ya.
E gosipụtara omume abụọ a iji welie uru metabolic ma kwalite oke ibu ibu ma e jiri ya tụnyere GLP-1 agonists naanị.
Atụmatụ Ọmụmụ SURMOUNT-1
SURMOUNT-1bụ arandomized, okpukpu abụọ kpuru, agba 3 ụlọ ọgwụemere n'ofe saịtị 119 na mba itoolu.
Ndị sonyere gụnyere ndị okenye bụ:
- Ibu ibu(BMI ≥ 30), ma ọ bụ
- Ibu oke ibu(BMI ≥ 27) nwere opekata mpe otu nsogbu metụtara ibu (dịka, ọbara mgbali elu, dyslipidemia, apnea nke ụra, ma ọ bụ ọrịa obi).
Ewepụrụ ndị nwere ọrịa shuga, iji ọgwụ na-efunahụ ibu na nso nso a, ma ọ bụ tupu ịwa ahụ bariatric.
E kenyere ndị so na ya ka ha nata injections otu ugboro kwa izu:
- Tirzepatide 5 mg, 10 mg, 15 mg, ma ọ bụ
- Placebo
Ndị niile sonyere nwetakwara ntụzịaka ụdị ndụ:
- A ụkọ calorie nke 500 kcal / ụbọchị
- OpekempeNkeji 150 nke mgbatị ahụ kwa izu
Ọgwụgwọ ahụ dịgidereIzu 72, gụnyere aUsoro mmụba dose-izu 20na-esote oge mmezi nke izu 52.
Nyochaa nsonaazụ
Ngụkọta nkeNdị sonyere 2,359e debanyere aha.
Nkezi afọ bụ44.9 afọ, 67.5% bụ ụmụ nwanyị, na ihe efuarọ ahụ nke 104.8 kgnaBMI nke 38.0.
Mbelata ịdị arọ nke ahụ pụtara na izu 72
| Otu dose | % Mgbanwe ibu | Mgbanwe ịdị arọ (kg) | Mfu agbakwunyere vs Placebo |
|---|---|---|---|
| 5 mg | -15.0% | -16.1 n'arọ | -13.5% |
| 10 mg | -19.5% | -22.2 n'arọ | -18.9% |
| 15 mg | -20.9% | -23.6 n'arọ | -20.1% |
| Placebo | -3.1% | -2,4 n'arọ | - |
Tirzepatide nwetara 15-21% pụtara mbelata ibu ahụ, na-egosipụta doro anya mmetụta dabere dose.
Pasent nke ndị sonyere na-enweta mbelata ibu arọ
| Mbelata ibu (%) | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| ≥5% | 85.1% | 88.9% | 90.9% | 34.5% |
| ≥10% | 68.5% | 78.1% | 83.5% | 18.8% |
| ≥15% | 48.0% | 66.6% | 70.6% | 8.8% |
| ≥20% | 30.0% | 50.1% | 56.7% | 3.1% |
| ≥25% | 15.3% | 32.3% | 36.2% | 1.5% |
Ihe karịrị ọkaranke ndị sonyere na-anata≥10 mgTirzepatide nwetara≥20% ọnwụ ọnwụ, na-abịaru nso mmetụta a na-ahụ na ịwa ahụ bariatric.
Uru Metabolic na Cardiovascular
E jiri ya tụnyere placebo, Tirzepatide mere nke ọma:
- okirikiri ukwu
- Systolic ọbara mgbali
- Profaịlụ lipid
- Ọkwa insulin na-ebu ọnụ
N'etiti ndị sonyere naọrịa shuga mellitus, 95.3% laghachiri na ọkwa glucose nkịtị, tụnyere61.9%N'ime otu placebo - na-egosi Tirzepatide ọ bụghị naanị na-enyere aka n'ibelata ibu, kamakwa na-eme ka metabolism glucose dịkwuo mma.
Nchekwa na nnabata
Mmetụta kachasị emetụta bụeriri afọ, gụnyereọgbụgbọ, afọ ọsịsa, na afọ ntachi, nke ka ukwuu dị nro na nke na-agafe agafe.
Ọnụego nkwụsị n'ihi ihe ọjọọ dị ihe dịka4–7%.
Ọnwụ ole na ole mere n'oge ikpe a, jikọtara ya na yaCOVID 19, na enweghị njikọ kpọmkwem na ọgwụ ọmụmụ.
Ọnweghị nnukwu ọdịiche a hụrụ na nsogbu ndị metụtara gallbladder.
Mkparịta ụka
Mgbanwe ụdị ndụ naanị (nri na mmega ahụ) na-arụpụta naanị~ 3% nkezi arọ ọnwụ, dị ka a hụrụ na placebo otu.
N'ụzọ dị iche, Tirzepatide nyeere15-21% mbelata ịdị arọ ahụ zuru oke, na-anọchi anya a5-7 ugboro ka ukwuu mmetụta.
Tụnyere:
- Ọgwụ na-ebelata ibu ọnụ:na-enwetakarị mfu 5-10%.
- Ịwa ahụ Bariatric:na-enweta> 20% mfu
Tirzepatide na-ejikọta ọdịiche dị n'etiti ọgwụ na ọgwụ na ịwa ahụ - inyeike, na-abụghị mbuso agha Mbelata arọ.
N'ụzọ dị mkpa, a hụghị nchegbu maka mbelata glucose metabolism. N'ụzọ megidere nke ahụ, Tirzepatide kwalitere mmetụta insulin na-atụgharị prediabetes n'ọtụtụ ndị sonyere.
Agbanyeghị, nnwale a tụnyere Tirzepatide na placebo - ọ bụghị ozugbo naSemaglutide.
Ọ dị mkpa ntụnyere isi na isi iji chọpụta nke na-emepụta ibu ibu ka ukwuu.
Mmechi
Maka ndị okenye nwere oke ibu ma ọ bụ oke ibu na nsogbu ndị metụtara ya, na-agbakwụnyeTirzepatide otu ugboro kwa izuna usoro ndụ ahaziri ahazi (nri + mmega ahụ) nwere ike ibute:
- 15–21% nkezi ịdị arọ ahụ mbelata
- Mgbanwe nke metabolic dị mkpa
- Nnukwu nnabata na nchekwa
Tirzepatide si otú a na-anọchite anya ọgwụgwọ dị irè na nke ụlọ ọgwụ kwadoro maka nlekọta ịdị arọ nke ahụike na-adịgide adịgide.
Oge nzipu: Ọktoba 16-2025